View Published SNOMED CT Subset Metadata

QOF Prescribable beta-adrenoceptor blockers for use in CHD


Subset Name :   
QOF Prescribable beta-adrenoceptor blockers for use in CHD
Subset Original Id :   
633701000001131
Subset Type :   
Realm Concept

Refset FSN :   
Quality and Outcomes Framework general practice extraction - beta-adrenoceptor blockers for use in coronary heart disease prescribable within general practice simple reference set (foundation metadata concept)
Refset Id :   
12464101000001102
Refset Type :   
Simple

Subset Description :
All VMPs and AMPs associated with the following VTMs: Sotalol, Bisoprolol, Carvedilol, Nebivolol, Bisoprolol + Hydrochlorothiazide, Bisoprolol + Aspirin, Metoprolol, Pindolol, Propranolol, Acebutolol. Esmolol, Nadolol, Timolol, Atenolol, Celiprolol, Atenolol + Bendroflumethiazide, Atenolol + Nifedipine, Nadolol + Bendroflumethiazine, Pindolol + Clopamide, Acebutolol + Hydrochlorothiazide, Propranolol + Bendroflumethiazide, Timolol + Bendroflumethiazide, Timolol + Travoprost, Timolol + Amiloride + Hydrocholorthiazide, Co-tenidone, Oxprenolol and Co-Prenoxzide. The subset also excludes all VMPs and AMPs that have any of the following drug forms: Eye drops, Ear drops, Eye ointment, Eye gel, Ear/eye drops solution, Ear/eye/nose drops solution. This subset, as currently published, supports the NHS England QOF business rules for 2016-2017. This subset may contain invalid concepts.

Status

Subset Status :   
Supported
Subset Status Date :   
Mar 30, 2016
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

   
Usage Type :    
Intended
Usage Description :    
Intended for secondary uses purposes. Management Information to support counts for establishing Quality and Outcomes Framework points used to determine Practice QOF payments. QOF Indicators Supported: Indicator CHD006: The percentage of patients with a history of myocardial infarction (on or after 1 April 2011) currently treated with an ACE-I (or ARB if ACE-I intolerant), aspirin or an alternative anti-platelet therapy, beta-blocker and statin. NICE clinical guidelines & advice: Prevention of cardiovascular disease PH25 https://www.nice.org.uk/guidance/ph25 These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. The subsets as published in the current release data are applicable to the QOF year 2016-2017.
Geographic Usage :    
England
Usage Category:    
 Quality Outcome Framework Prescribable


Scope :

   
Inclusion Criteria :   
Age group - any age; Gender - not specified; Sex - not specified
Subject Category :   
Prescribing; Chemicals and Drugs; Disciplines and Occupations

Publication

Subset Release Category :   
UK Drug Extension
Language :   
en
Folder Name :   
QOF
File Name :   
der1_SubsetMembers_QOFPresBetaAdrenBlockInCHD_GB1000001_YYYYMMDD

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
6.0
Last Updated :   
Feb 14, 2018

Related Links

Subset download with descriptions :

UK Drug Extension releases